OncoMatch/Clinical Trials/NCT05589896
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Is NCT05589896 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies non-drug interventions for acute leukemia.
The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute and chronic leukemias, myelodysplastic syndrome, and certain lymphomas. Patients will either receive myeloablative conditioning or reduced intensity conditioning regimen prior to the transplant. Patients will be followed for 56 days for safety endpoints and remain in follow-up for one year.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Myelodysplastic Syndrome
Non-Hodgkin Lymphoma
Disease stage
Required: Stage FIRST REMISSION OR BEYOND
in the first remission or beyond with ≤5% marrow blasts documented by bone marrow assessment and no circulating blasts or extra-medullary disease within 42 days prior to anticipated start of conditioning
Prior therapy
Cannot have received: autologous or allogeneic hematopoietic cell transplant
Prior autologous or allogeneic HCT
Lab requirements
Kidney function
SCr within 1.5x normal range for age. If SCr is outside normal range for age, CrCl> 60 mL/min/1.73m2 must be obtained
Liver function
total bilirubin ≤2.0 mg/dL, and ALT, AST, and ALP <3 x upper limit normal (ULN), unless ALT, AST, and/or ALP are disease related
Cardiac function
LVEF at rest ≥40% (RIC) or LVEF at rest ≥45% (MAC)
Adequate organ function defined as: Cardiac: LVEF at rest ≥40% (RIC) or LVEF at rest ≥45% (MAC); Pulmonary: DLCO, FEV1, FVC ≥50% predicted by pulmonary function tests (PFTs). DLCO value may be corrected for hemoglobin; Hepatic: total bilirubin ≤2.0 mg/dL, and ALT, AST, and ALP <3 x upper limit normal (ULN), unless ALT, AST, and/or ALP are disease related; Renal: SCr within 1.5x normal range for age. If SCr is outside normal range for age, CrCl> 60 mL/min/1.73m2 must be obtained
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- Moffitt Cancer Center · Tampa, Florida
- Emory University - Winship Cancer Institute · Atlanta, Georgia
- Henry Ford Cancer Institute · Detroit, Michigan
- Oregon Health and Science University · Portland, Oregon
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify